GT200200071A - PHENYL-HETEROCICLIL-ETERES - Google Patents

PHENYL-HETEROCICLIL-ETERES

Info

Publication number
GT200200071A
GT200200071A GT200200071A GT200200071A GT200200071A GT 200200071 A GT200200071 A GT 200200071A GT 200200071 A GT200200071 A GT 200200071A GT 200200071 A GT200200071 A GT 200200071A GT 200200071 A GT200200071 A GT 200200071A
Authority
GT
Guatemala
Prior art keywords
disorder
obsessive
heterociclil
eteres
phenyl
Prior art date
Application number
GT200200071A
Other languages
Spanish (es)
Inventor
Mavis Diane Adam
Mark David Andrews
Geoffrey Edward Gymer
David Hepworth
Harry Ralph Howard Jr
Donald Stuart Middleton
Alan Stobie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GT200200071A publication Critical patent/GT200200071A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS QUE INHIBEN LA REABSORCION DE MONOAMINAS, ESPECIALMENTE DE LA SEROTONINA DE FORMULA GENERAL (I) EN DONDE R1,R2,Y,W,Z,A,B,L,U,M,Q, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON UTILES EN ESTADOS DE DEPRESION, TRASTORNO DE HIPERACTIVIDAD CON DEFICIT DE ATENCION, TRASTORNO OBSESIVOCOMPULSIVO, TRASTORNO POR ABUSO DE SUSTANCIAS Y DISFUNCION SEXUAL, INCLUYENDO EYACULACION PRECOZ.THE PRESENT INVENTION REFERS TO NEW COMPOUNDS THAT INHIBIT THE REABSORTION OF MONOAMINS, ESPECIALLY OF THE SEROTONIN OF GENERAL FORMULA (I) WHERE R1, R2, Y, W, Z, A, B, L, U, M, Q, ARE FUNCTIONAL GROUPS DESCRIBED ON THE RECORD. THESE COMPOUNDS ARE USEFUL IN STATES OF DEPRESSION, HYPERACTIVITY DISORDER WITH DEFICIT OF ATTENTION, OBSESSIVE CO-OBSESSIVE DISORDER, DISORDER FOR SUBSTANCE ABUSE AND SEXUAL DYSFUNCTION, INCLUDING EFFECTIVE EJACULATION.

GT200200071A 2001-04-11 2002-04-11 PHENYL-HETEROCICLIL-ETERES GT200200071A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0109103.2A GB0109103D0 (en) 2001-04-11 2001-04-11 Novel compounds

Publications (1)

Publication Number Publication Date
GT200200071A true GT200200071A (en) 2003-01-31

Family

ID=9912700

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200071A GT200200071A (en) 2001-04-11 2002-04-11 PHENYL-HETEROCICLIL-ETERES

Country Status (44)

Country Link
EP (1) EP1377550B9 (en)
JP (1) JP2005504728A (en)
KR (1) KR100570376B1 (en)
CN (1) CN1656072A (en)
AP (1) AP1543A (en)
AR (1) AR035818A1 (en)
AT (1) ATE281435T1 (en)
AU (1) AU2002244898B2 (en)
BG (1) BG108204A (en)
BR (1) BR0208812A (en)
CA (1) CA2443699A1 (en)
CZ (1) CZ20032677A3 (en)
DE (1) DE60201819T2 (en)
DO (1) DOP2002000371A (en)
EA (1) EA008936B1 (en)
EC (1) ECSP034802A (en)
EE (1) EE200300498A (en)
ES (1) ES2227448T3 (en)
GB (1) GB0109103D0 (en)
GE (1) GEP20053590B (en)
GT (1) GT200200071A (en)
HR (1) HRP20030824A2 (en)
HU (1) HUP0303880A2 (en)
IL (2) IL158141A0 (en)
IS (1) IS6960A (en)
MA (1) MA27010A1 (en)
MX (1) MXPA03009383A (en)
MY (1) MY136262A (en)
NO (1) NO20034525L (en)
NZ (1) NZ528481A (en)
OA (1) OA12500A (en)
PA (1) PA8543701A1 (en)
PE (1) PE20021003A1 (en)
PL (1) PL373533A1 (en)
PT (1) PT1377550E (en)
RS (1) RS79703A (en)
SI (1) SI1377550T1 (en)
SK (1) SK12452003A3 (en)
SV (1) SV2003000981A (en)
TN (1) TNSN03090A1 (en)
UA (1) UA74430C2 (en)
UY (1) UY27250A1 (en)
WO (1) WO2002083643A1 (en)
ZA (1) ZA200307507B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256085A1 (en) * 2001-04-06 2002-10-21 Smithkline Beecham Corporation Quinoline inhibitors of hyak1 and hyak3 kinases
MY140236A (en) * 2002-09-19 2009-12-31 Lilly Co Eli Diarylether compounds useful as opioid receptor antagonists
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
WO2006008635A1 (en) * 2004-07-14 2006-01-26 Pfizer Limited Process for the preparation of a 3-phenoxy-pyridine derivative
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
CN103554095A (en) 2006-02-15 2014-02-05 Abbvie公司 Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2008079610A2 (en) * 2006-12-21 2008-07-03 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
BRPI0806498A2 (en) 2007-01-04 2014-04-22 Prosidion Ltd GPCR PIPERIDINE AGONISTS
DE102008053242A1 (en) 2008-10-25 2010-05-06 Saltigo Gmbh Heteroaryl-aryl ether
JP2014001199A (en) * 2012-01-25 2014-01-09 Ishihara Sangyo Kaisha Ltd Pest control agent
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
KR20210135521A (en) 2019-03-06 2021-11-15 다이이찌 산쿄 가부시키가이샤 pyrrolopyrazole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100441A (en) * 1999-02-23 2002-12-16 Pfizer Products Inc. Monoamine reuptake inhibitors for the treatment of central nervous system disorders
CN1242995C (en) * 1999-05-21 2006-02-22 比奥维特罗姆股份公司 Novel compounds, their use and preparation
AP2002002481A0 (en) * 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.

Also Published As

Publication number Publication date
AU2002244898B2 (en) 2007-05-24
BR0208812A (en) 2004-03-09
PT1377550E (en) 2005-01-31
DE60201819D1 (en) 2004-12-09
AR035818A1 (en) 2004-07-14
PA8543701A1 (en) 2004-05-26
NZ528481A (en) 2006-02-24
CZ20032677A3 (en) 2004-06-16
EP1377550B9 (en) 2005-11-23
ES2227448T3 (en) 2005-04-01
UY27250A1 (en) 2002-12-31
EA008936B1 (en) 2007-10-26
IL158141A0 (en) 2004-03-28
GB0109103D0 (en) 2001-05-30
SI1377550T1 (en) 2005-02-28
AP1543A (en) 2006-01-11
NO20034525L (en) 2003-12-08
SV2003000981A (en) 2003-07-29
EP1377550A1 (en) 2004-01-07
ECSP034802A (en) 2003-12-01
MA27010A1 (en) 2004-12-20
ATE281435T1 (en) 2004-11-15
PE20021003A1 (en) 2002-11-12
KR20030088133A (en) 2003-11-17
AP2002002468A0 (en) 2002-06-30
KR100570376B1 (en) 2006-04-11
TNSN03090A1 (en) 2005-12-23
UA74430C2 (en) 2005-12-15
MXPA03009383A (en) 2004-01-29
RS79703A (en) 2006-12-15
CN1656072A (en) 2005-08-17
CA2443699A1 (en) 2002-10-24
EE200300498A (en) 2004-02-16
IS6960A (en) 2003-09-18
DE60201819T2 (en) 2005-11-03
OA12500A (en) 2006-05-24
JP2005504728A (en) 2005-02-17
IL158141A (en) 2007-10-31
SK12452003A3 (en) 2004-08-03
HUP0303880A2 (en) 2004-04-28
NO20034525D0 (en) 2003-10-09
PL373533A1 (en) 2005-09-05
EP1377550B1 (en) 2004-11-03
EA200300988A1 (en) 2004-04-29
WO2002083643A1 (en) 2002-10-24
MY136262A (en) 2008-09-30
HRP20030824A2 (en) 2005-08-31
GEP20053590B (en) 2005-07-25
BG108204A (en) 2004-12-30
DOP2002000371A (en) 2002-10-15
ZA200307507B (en) 2004-11-19

Similar Documents

Publication Publication Date Title
GT200200210A (en) ALKINS AS MATRIX METALOPROTEINASE INHIBITORS
GT200300150A (en) KINASE INHIBITORS
GT200400161A (en) REPLACED PYRIDINONES
GT200600342A (en) AMINO-HYDANTOINE CYCLALQUIL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF BETA-SECRETASE
GT200300101A (en) PIRAZOLOPIRIDINS SUBSTITUTED WITH CARBAMATE
ECSP034600A (en) LACTAMA COMPOUNDS
BR122012023120B8 (en) Serotonin reuptake inhibitor compound
GT200200043A (en) NEW BENCIMIDAZOL ANTI-INFLAMMATORY COMPOUNDS
GT200300292A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
GT200100146A (en) ACTIVITIES OF GLUCOQUINASE ACETAMIDE BENZENICA REPLACED WITH ALFA-ACILO AND ALFA-HETEROATOMO ATOMS.
GT200300005A (en) 2- (PIRIDIN-2-ILAMINO) -PIRIDO [2,3-D] PIRIMIDIN-7-ONAS
BR0115436A (en) Piperazinylpyrazine Compounds Acting as Serotonin 5ht-2 Receptor Antagonists
GT200200042A (en) NEW TRIAZOLOPIRIDIN ANTI-INFLAMMATORY COMPOUNDS
GT200400032A (en) NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
GT200400092A (en) PREPARATION AND USE OF RENTAL DERIVATIVES FOR THE TREATMENT OF OBESITY
DK1627050T3 (en) HUMICOLA GRISEA CBH1.1 VARIANT
BR9901279A (en) Replaced tricycles
ECSP034802A (en) FENIL - HETEROCICLIL- ETERES
DE602004005888D1 (en) MANUFACTURE OF SELF-ORGANIZED MONOSLAYS
GT200300046A (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS AND PROCEDURES FOR USE
GT200300082A (en) INHIBITORS TRIARILOXIARILOXIPIRIMIDINA-2,4,6-METALOPROTEINASE TRION
GT200400041A (en) AZABICICLIC DERIVATIVES OF PIRIDILOXIMETILO AND BENCISOXAZOL
GT200400188A (en) 5-ARILPIRIMIDINAS AS ANTICANCERIGEN AGENTS
GT200100182A (en) FUNGICIDE COMPOSITIONS.
AR021446A1 (en) CLEANING COMPOSITIONS